Moffitt Trial Reports Higher Survival for HER2-Positive Breast Cancer Patients With Leptomeningeal Metastases

The phase 2 trial shows patients treated with radiation therapy followed by two antibodies delivered intrathecally had a median overall survival of 36 months

Kosj Yamoah, MD, PhD, had just started working at Moffitt Cancer Center as a radiation oncologist when his son, Zion, was diagnosed with a rare and aggressive childhood brain cancer.

A Father’s Promise

In his short life, Zion Yamoah left a long legacy that continues with new proton therapy center

Heather Curley enjoys some family time with her daughter, Palmer, and husband, Dennis. When Heather was diagnosed with leptomeningeal disease, her prognosis was only two to four months.

Dendritic Cell Trial Brings Hope for Young Mom With Leptomeningeal Disease

Given just weeks to live, Heather Curley had no time to waste

Highlighting Moffitt’s Top Research Stories of 2025

Breakthrough discoveries that shaped cancer science in 2025

A researcher puts liquid on a petri dish.

New Hope on the Horizon for Fighting Leptomeningeal Disease

Targeting branched-chain keto acids with phenylbutyrate could lead to better outcomes for those with leptomeningeal disease

Radiation Therapy Can Reduce Symptoms in Patients With Leptomeningeal Disease

Study showed intensity-modulated radiation craniospinal irradiation improved side effects in 77% of patients

Moffitt Offers Breakthrough Therapy for Leptomeningeal Disease

Cancer center is first and only place offering dendritic cell vaccine for hard to treat disease

‘So That Others May Live’

That motto guided Sara Davis’s decision to donate everything so others could have a better quality of life

Endeavor

Cambiar el idioma